We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

Abbott Diagnostics

Abbott Diagnostics provides medical diagnostic instruments, tests, automation and informatics solutions, including cl... read more Featured Products: More products

Download Mobile App




Events

09 Apr 2024 - 12 Apr 2024
15 Apr 2024 - 17 Apr 2024
23 Apr 2024 - 26 Apr 2024

Low Anti-SARS-CoV-2 S Antibody Levels Predict Increased Mortality

By LabMedica International staff writers
Posted on 20 Oct 2021
Print article
Image: Low anti-SARS-CoV-2 S antibody levels predict increased mortality and dissemination of viral components in the blood of critical COVID-19 patients (Photo courtesy of Instituto de Salud Carlos III)
Image: Low anti-SARS-CoV-2 S antibody levels predict increased mortality and dissemination of viral components in the blood of critical COVID-19 patients (Photo courtesy of Instituto de Salud Carlos III)
Anti-SARS-CoV-2 spike (S) antibodies bind to multiple domains in this viral protein. Host antibodies directed at the receptor binding domain (RBD) mediate inhibition of viral attachment to cell surface receptors.

Anti-S antibodies could play a role in reducing viral replication during an ongoing acute infection by interfering with virus entry into a cell. Interestingly, whether levels of host-produced endogenous antibodies against the S protein could influence mortality risk in severe COVID-19 has not been sufficiently studied.

A large team of medical scientists associated with the Instituto de Salud Carlos III (Madrid, Spain) recruited 92 critically ill adult patients with a positive nasopharyngeal swab polymerase chain reaction (PCR) test for SARS-CoV-2 from 16th March to 15th April 2020, during the first pandemic wave from several hospitals. They obtained EDTA plasma in the first 24 hours following admission to the Intensive Care Unit (ICU).

The scientists quantified SARS-CoV-2 RNA in plasma using the Bio-Rad SARS-CoV-2 droplet digital PCR kit (Bio-Rad, Hercules, CA, USA). The team developed a specific immunoassay to quantify anti-SARS-CoV-2 S IgG and IgM antibodies in plasma and evaluated the presence/absence of N antigen of SARS-CoV-2 in plasma using the Panbio COVID-19 Ag Rapid Test Device (Abbott, Chicago, IL, USA).

The investigators reported that the frequency of N-antigenaemia was >2.5-fold higher in absence of antibodies. Ten patients (of the total cohort) had no detectable levels in the plasma of anti-SARS-CoV-2 S IgG, and 13 had no detectable levels of anti-SARS-CoV-2 S IgM. Patients who died showed more often absence/lower levels of anti-SARS-CoV-2 S IgM and IgG than those who survived by day 30 following ICU admission. In contrast to that observed for antibodies, non-survivors showed more frequently the presence of antigenaemia along with higher viral RNA loads in plasma. Antibodies correlated inversely with viral RNA-load in plasma, representing a protective factor against mortality. Viral RNA-load in plasma and N-antigenaemia predicted increased mortality.

Jesús F. Bermejo-Martin, MD, PhD, a Clinical Immunologist and a co-senior author of the study, said, “Our findings support that treatment with exogenous antibodies in COVID-19 should be personalized, reserving this therapy for those patients with absent or low endogenous antibodies levels.”

The authors concluded that low anti-SARS-CoV-2 S antibody levels predict mortality in critical COVID-19 and their findings support that these antibodies contribute to prevent systemic dissemination of SARS-CoV-2. The study was published on October 5, 2021 in the Journal of Internal Medicine.

Related Links:
Instituto de Salud Carlos III
Bio-Rad
Abbott


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
HLX
Complement 3 (C3) Test
GPP-100 C3 Kit
New
Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more

Pathology

view channel
Image: The OvaCis Rapid Test discriminates benign from malignant epithelial ovarian cysts (Photo courtesy of INEX)

Intra-Operative POC Device Distinguishes Between Benign and Malignant Ovarian Cysts within 15 Minutes

Ovarian cysts represent a significant health issue for women globally, with up to 10% experiencing this condition at some point in their lives. These cysts form when fluid collects within a thin membrane... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.